Trial Profile
A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Aug 2015 New source identified and integrated: University Hospital Medical Information Network - Japan [UMIN000004659].
- 06 Aug 2015 New trial record